Rubric Capital Management (New York)’s Stemline Therapeutics, Inc. STML Stock Holding History

Rubric Capital Management (New York)’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3,347,141	Closed	-$16.2M	–	72
2020 Q1	$16.2M	Sell	3,347,141 -152,859	-4%	-$991K	2.56%	16
2019 Q4	$37.2M	Buy	3,500,000 +917,567	+36%	+$9.11M	4.21%	8
2019 Q3	$26.9M	Sell	2,582,433 -243,971	-9%	-$3.19M	2.46%	12
2019 Q2	$43.3M	Sell	2,826,404 -178,596	-6%	-$2.58M	3.41%	5
2019 Q1	$38.6M	Buy	+3,005,000	New	+$34M	3.61%	5

Rubric Capital Management (New York)'s STML Position: Q2 2020 in Review

Rubric Capital Management (New York) sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 3,347,141 shares — an estimated $16.2M sold.

Rubric Capital Management (New York) first reported a position in STML in Q1 2019 and held it in 5 quarters. The position peaked at $43.3M in Q2 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

Rubric Capital Management (New York) reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
Rubric Capital Management (New York) sold 3,347,141 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $16.2M.
Rubric Capital Management (New York) first reported a position in Stemline Therapeutics, Inc. in Q1 2019 and held it in 5 quarters.
Rubric Capital Management (New York)'s Stemline Therapeutics, Inc. position peaked at $43.3M in Q2 2019.
0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on Rubric Capital Management (New York)'s 13F filing for Q2 2020, filed 10 Aug 2020.